Stati Uniti - inglese - NLM (National Library of Medicine)

dr.reddy’s laboratories inc - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole tablets are indicated for the treatment of: additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs, including

Stati Uniti - inglese - NLM (National Library of Medicine)

macleods pharmaceuticals limited - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole oral tablets are indicated for the treatment of: • schizophrenia •  irritability associated with autistic disorder (14.4) • treatment of tourette’s disorder (14.5) aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/.  risk summary neonates exposed to antipsychotic drugs, including aripiprazole, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery (see c

Stati Uniti - inglese - NLM (National Library of Medicine)

proficient rx lp - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole oral tablets are indicated for the treatment of: additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole tablets are contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] .  pregnancy category c pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs (including aripiprazole) during the third trimester of pregnancy

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

apotex nz ltd - aripiprazole 30mg - tablet - 30 mg - active: aripiprazole 30mg excipient: croscarmellose sodium iron oxide red magnesium stearate microcrystalline cellulose tartaric acid - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; hyprolose; magnesium stearate - aripiprazole gh is indicated for: ? the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy; ? acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate. ? maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; hyprolose; magnesium stearate - aripiprazole gh is indicated for: ? the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy; ? acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate. ? maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; hyprolose; magnesium stearate - aripiprazole gh is indicated for: ? the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy; ? acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate. ? maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - aripiprazole, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; hyprolose; magnesium stearate - aripiprazole gh is indicated for: ? the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy; ? acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate. ? maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; hyprolose; magnesium stearate - aripiprazole gh is indicated for: ? the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy; ? acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate. ? maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Stati Uniti - inglese - NLM (National Library of Medicine)

solco healthcare u.s., llc - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole tablets are indicated for the treatment of: aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs, including aripiprazole, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery (see clinical considerations) . overall available data from published epidemiologic studies of pregnant women exposed to aripiprazole have not est